Telmisartan
- Generic Name
- Telmisartan
- Brand Names
- Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta, Tolura, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Telmisartan Teva Pharma, Telmisartan Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C33H30N4O2
- CAS Number
- 144701-48-4
- Unique Ingredient Identifier
- U5SYW473RQ
- Background
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arter...
- Indication
Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hypertension
- Associated Therapies
- -
HIV and Fat Accumulation
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 35
- Registration Number
- NCT01088295
- Locations
- 🇺🇸
UCLA CARE Center, Los Angeles, California, United States
Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 66
- Registration Number
- NCT00981526
- Locations
- 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise
- Conditions
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18299
- Registration Number
- NCT00946829
- Locations
- 🇾🇪
Boehringer Ingelheim Investigational Site, Boehringer Ingelheim Investigational Site, Yemen
The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome
- First Posted Date
- 2009-06-23
- Last Posted Date
- 2009-06-24
- Lead Sponsor
- Aligarh Muslim University
- Target Recruit Count
- 110
- Registration Number
- NCT00926341
- Locations
- 🇮🇳
Department of Medicine, J.N.Medical,College, AMU,Aligarh, Aligarh, Uttar Pradesh, India
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
- First Posted Date
- 2009-06-23
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 894
- Registration Number
- NCT00926289
- Locations
- 🇺🇸
502.550.01007 Boehringer Ingelheim Investigational Site, Greensboro, North Carolina, United States
🇨🇳502.550.86002 Boehringer Ingelheim Investigational Site, Shanghai, China
🇨🇳502.550.86007 Boehringer Ingelheim Investigational Site, Tianjin, China
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal
- Conditions
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 822
- Registration Number
- NCT00865020
- Locations
- 🇻🇪
Investigative Site, Caracas, Venezuela
🇭🇺Invesitagtive Site, Budapest, Hungary
Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
- Conditions
- Interventions
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 858
- Registration Number
- NCT00860262
- Locations
- 🇧🇬
1235.20.008 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria
🇭🇺1235.20.152 Boehringer Ingelheim Investigational Site, Budapest, Hungary
🇷🇴1235.20.254 Boehringer Ingelheim Investigational Site, Iasi, Romania
Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.
- Conditions
- Interventions
- First Posted Date
- 2008-09-10
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 405
- Registration Number
- NCT00750113
Telmisartan Versus Ramipril After Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2008-06-20
- Lead Sponsor
- Catholic University of the Sacred Heart
- Target Recruit Count
- 50
- Registration Number
- NCT00702936
- Locations
- 🇮🇹
Catholic University of the Sacred Heart, Rome, Italy
J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 21471
- Registration Number
- NCT00659581
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.